Intensive Care Medicine

, Volume 37, Issue 4, pp 632–638 | Cite as

Optimization of meropenem dosage in the critically ill population based on renal function

  • Jared L. Crandon
  • Robert E. Ariano
  • Sheryl A. Zelenitsky
  • Anthony M. Nicasio
  • Joseph L. Kuti
  • David P. NicolauEmail author



To develop a meropenem population pharmacokinetic model in critically ill patients with particular focus on optimizing dosing regimens based on renal function.


Population pharmacokinetic analysis was performed with creatinine clearance (CrCl) and adjusted body weight to predict parameter estimates. Initial modeling was performed on 21 patients (55 samples). Validation was conducted with 12 samples from 5 randomly selected patients excluded from the original model. A 5,000-patient Monte Carlo simulation was used to ascertain optimal dosing regimens for three CrCl ranges.


Mean ± SD age, APACHE, and CrCl were 59.2 ± 16.8 years, 13.6 ± 7, and 78.3 ± 33.7 mL/min. Meropenem doses ranged from 0.5 g every 8 h (q8h)–2 g q8h as 0.5–3 h infusions. Median estimates for volume of the central compartment, K 12, and K 21 were 0.24 L/kg, 0.49 h−1, and 0.65 h−1, respectively. K 10 was described by the equation: K 10 = 0.3922 + 0.0025 × CrCl. Model bias and precision were −1.9 and 8.1 mg/L. R 2, bias, and precision for the validation were 93%, 1.1, and 2.6 mg/L. At minimum inhibitory concentrations (MICs) up to 8 mg/L, the probability of achieving 40% fT > MIC was 96, 90, and 61% for 3 h infusions of 2 g q8h, 1 g q8h, and 1 g q12h in patients with CrCl ≥50, 30–49, and 10–29, respectively. Target attainment was 75, 65, and 44% for these same dosing regimens as 0.5 h infusions.


This pharmacokinetic model is capable of accurately estimating meropenem concentrations in critically ill patients over a range of CrCl values. Compared with 0.5 h infusions, regimens employing prolonged infusions improved target attainment across all CrCl ranges.


Meropenem Population pharmacokinetics Prolonged infusion Creatinine clearance Monte Carlo simulation 



We would like to thank Christina Sutherland for her assistance with the analytical determination of meropenem and Aryun Kim, Pharm.D. for her assistance with collection of pharmacokinetic samples.

Supplementary material

134_2010_2105_MOESM01_ESM.doc (28 kb)
Online Resource 1. Covariance matrix for the derived pharmacokinetic parameters. (DOC 28 kb)


  1. 1.
    Merrem (2007) (Meropenem) package insert. AstraZeneca, WilmingtonGoogle Scholar
  2. 2.
    Li C, Kuti JL, Nightingale CH, Nicolau DP (2006) Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 46:1171–1178CrossRefPubMedGoogle Scholar
  3. 3.
    Clinical Laboratory Standard Institute (2008) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI Publication M07-A8, WayneGoogle Scholar
  4. 4.
    DeRyke CA, Kuti JL, Nicolau DP (2007) Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 58:337–344CrossRefPubMedGoogle Scholar
  5. 5.
    Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T (2008) Development of breakpoints of carbapenems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in peritoneal fluid. J Infect Chemother 14:330–332CrossRefPubMedGoogle Scholar
  6. 6.
    Drusano GL (2004) Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 2:289–300CrossRefPubMedGoogle Scholar
  7. 7.
    Turnidge JD (1998) The pharmacodynamics of beta-lactams. Clin Infect Dis 27:10–22CrossRefPubMedGoogle Scholar
  8. 8.
    Eggimann P, Pittet D (2001) Infection control in the ICU. Chest 120:2059–2093CrossRefPubMedGoogle Scholar
  9. 9.
    Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840–851 quiz 859CrossRefPubMedGoogle Scholar
  10. 10.
    Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA (2001) Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 45:13–22CrossRefPubMedGoogle Scholar
  11. 11.
    Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL (2009) Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 25:69–77CrossRefPubMedGoogle Scholar
  12. 12.
    Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J (2009) Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 64:142–150CrossRefPubMedGoogle Scholar
  13. 13.
    Elkhaili H, Niedergang S, Pompei D, Linger L, Leveque D, Jehl F (1996) High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B Biomed Appl 686:19–26CrossRefPubMedGoogle Scholar
  14. 14.
    Leary RJ, Schumitzky A, Van Guilder M (2001) An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In: Proceedings, fouteenth IEEE symposium on computer-based medical systems. IEEE Computer Society, Bethesda, pp 389–394Google Scholar
  15. 15.
    Crandon JL, Kuti JL, Jones RN, Nicolau DP (2009) Comparison of 2002–2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann Pharmacother 43:220–227PubMedGoogle Scholar
  16. 16.
    Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA (2002) Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 19:105–110CrossRefPubMedGoogle Scholar
  17. 17.
    Krueger WA, Bulitta J, Kinzig-Schippers M, Landersdorfer C, Holzgrabe U, Naber KG, Drusano GL, Sorgel F (2005) Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 49:1881–1889CrossRefPubMedGoogle Scholar
  18. 18.
    Lee DG, Choi SM, Shin WS, Lah HO, Yim DS (2006) Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea. Int J Antimicrob Agents 28:333–339CrossRefPubMedGoogle Scholar
  19. 19.
    Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR (2005) Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 44:539–549CrossRefPubMedGoogle Scholar
  20. 20.
    Thalhammer F, Traunmuller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, Stoiser B, Staudinger T, Thalhammer-Scherrer R, Burgmann H (1999) Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 43:523–527CrossRefPubMedGoogle Scholar
  21. 21.
    Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C (1999) Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int 55:1878–1884CrossRefPubMedGoogle Scholar
  22. 22.
    Lipman J, Wallis SC, Boots RJ (2003) Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 97:1149–1154 (table of contents)CrossRefPubMedGoogle Scholar
  23. 23.
    Chow KM, Hui AC, Szeto CC (2005) Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 24:649–653CrossRefPubMedGoogle Scholar
  24. 24.
    Bulik CC, Quintiliani Jr R, Samuel Pope J, Kuti JL, Nicolau DP (2009) Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis—a review of 3 cases. Resp Med CME E pubGoogle Scholar
  25. 25.
    Li C, Du X, Kuti JL, Nicolau DP (2007) Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51:1725–1730CrossRefPubMedGoogle Scholar

Copyright information

© Copyright jointly held by Springer and ESICM 2010

Authors and Affiliations

  • Jared L. Crandon
    • 1
  • Robert E. Ariano
    • 2
  • Sheryl A. Zelenitsky
    • 2
  • Anthony M. Nicasio
    • 1
  • Joseph L. Kuti
    • 1
  • David P. Nicolau
    • 1
    Email author
  1. 1.Center for Anti-Infective Research and DevelopmentHartford HospitalHartfordUSA
  2. 2.Department of Pharmacy, St. Boniface General Hospital and Faculty of PharmacyUniversity of ManitobaWinnipegCanada

Personalised recommendations